CN100506272C - 一种治疗银屑病的中药制剂 - Google Patents
一种治疗银屑病的中药制剂 Download PDFInfo
- Publication number
- CN100506272C CN100506272C CNB2006100115180A CN200610011518A CN100506272C CN 100506272 C CN100506272 C CN 100506272C CN B2006100115180 A CNB2006100115180 A CN B2006100115180A CN 200610011518 A CN200610011518 A CN 200610011518A CN 100506272 C CN100506272 C CN 100506272C
- Authority
- CN
- China
- Prior art keywords
- parts
- rhizoma
- chinese medicine
- medicine preparation
- zaocys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 201000004681 Psoriasis Diseases 0.000 title abstract description 11
- 241000628997 Flos Species 0.000 claims description 28
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 17
- 230000001185 psoriatic effect Effects 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 8
- 241001598107 Imperata Species 0.000 claims description 7
- 241000931705 Cicada Species 0.000 claims description 5
- 239000008280 blood Substances 0.000 abstract description 23
- 210000004369 blood Anatomy 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 19
- 238000001816 cooling Methods 0.000 abstract description 6
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000006870 function Effects 0.000 abstract description 2
- 230000035876 healing Effects 0.000 abstract description 2
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 241000334160 Isatis Species 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 241000270295 Serpentes Species 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 239000000796 flavoring agent Substances 0.000 description 14
- 235000019634 flavors Nutrition 0.000 description 14
- 239000000843 powder Substances 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 7
- 238000001035 drying Methods 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 208000037920 primary disease Diseases 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010068319 Oropharyngeal pain Diseases 0.000 description 4
- 201000007100 Pharyngitis Diseases 0.000 description 4
- 206010043458 Thirst Diseases 0.000 description 4
- 208000001780 epistaxis Diseases 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- -1 suck Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010017553 Furuncle Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000034507 Haematemesis Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 201000007227 lymph node tuberculosis Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229940023488 pill Drugs 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010061245 Internal injury Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- 241000475481 Nebula Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 206010019847 hepatosplenomegaly Diseases 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010052369 Encephalitis lethargica Diseases 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000008127 lead poisoning Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 208000010540 rapid respiration Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100115180A CN100506272C (zh) | 2006-03-20 | 2006-03-20 | 一种治疗银屑病的中药制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100115180A CN100506272C (zh) | 2006-03-20 | 2006-03-20 | 一种治疗银屑病的中药制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1857667A CN1857667A (zh) | 2006-11-08 |
CN100506272C true CN100506272C (zh) | 2009-07-01 |
Family
ID=37296655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100115180A Expired - Fee Related CN100506272C (zh) | 2006-03-20 | 2006-03-20 | 一种治疗银屑病的中药制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100506272C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100522137C (zh) * | 2007-02-16 | 2009-08-05 | 遵义医学院附属医院 | 治疗银屑病的乳膏剂及其制备方法 |
-
2006
- 2006-03-20 CN CNB2006100115180A patent/CN100506272C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1857667A (zh) | 2006-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102357146B (zh) | 一种治疗脚气的中药 | |
CN100415265C (zh) | 一种治疗湿疹的中药制剂 | |
CN103830639A (zh) | 一种治疗湿疹的药物及其制备方法 | |
CN100546618C (zh) | 一种治疗银屑病的中药制剂 | |
CN100415278C (zh) | 一种治疗湿疹的中药制剂 | |
CN100415288C (zh) | 一种治疗银屑病的中药制剂 | |
CN101028491B (zh) | 一种治疗带状疱疹的中药制剂 | |
CN102579975B (zh) | 一种治疗银屑病的中药混合物 | |
CN100431578C (zh) | 一种治疗前列腺增生的中药制剂 | |
CN100506272C (zh) | 一种治疗银屑病的中药制剂 | |
CN100415277C (zh) | 一种治疗银屑病的中药制剂 | |
CN100571751C (zh) | 一种治疗银屑病的中药制剂 | |
CN100571725C (zh) | 一种治疗坐骨神经痛的中药制剂 | |
CN101095905A (zh) | 一种治疗银屑病的中药制剂 | |
CN101028421B (zh) | 一种治疗慢性肾衰的中成药 | |
CN100546623C (zh) | 一种治疗银屑病的中药制剂 | |
CN101912513B (zh) | 一种治疗湿疹的中药制剂 | |
CN105106574A (zh) | 一种中药组合物在治疗不孕不育中的应用 | |
CN100450537C (zh) | 一种治疗前列腺增生的中药制剂 | |
CN101085249A (zh) | 一种治疗月经先期的中药 | |
CN100382831C (zh) | 一种治疗湿疹的中药制剂 | |
CN100486629C (zh) | 一种治疗银屑病的中药制剂 | |
CN101069736A (zh) | 一种治疗银屑病的中药制剂 | |
CN105434874A (zh) | 一种治疗毛囊炎的药物及其制备方法 | |
CN103611098B (zh) | 一种治疗皮肤瘙痒的中药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING SINO-US INNOVATION INSTITUTE OF INTERNATIO Free format text: FORMER OWNER: WANG XINSUO Effective date: 20110413 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100072 CHANGXINDIAN HOSPITAL, FENGTAI DISTRICT, BEIJING TO: 100076 NO. 10, EAST ALLEY 6, NORTH AREA, MINSHENG ROAD, VILLAGE 4, XIHONGMEN TOWN, DAXING DISTRICT, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110413 Address after: 100076, No. six, No. 10, North East Road, Minsheng Road, fourth village, Xihongmen Town, Beijing, Daxing District Patentee after: Beijing Sino US Joint Institute of innovation and international difficult diseases Address before: 100072 Beijing Fengtai Changxindian Hospital Patentee before: Wang Xinsuo |
|
ASS | Succession or assignment of patent right |
Owner name: CHEN YUTANG Free format text: FORMER OWNER: BEIJING SINO-US INNOVATION INSTITUTE OF INTERNATIONAL STUBBORN DISEASES Effective date: 20120316 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Yutang Inventor before: Wang Xinsuo |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WANG XINSUO TO: CHEN YUTANG |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120316 Address after: 100076, Beijing Town, Daxing District Town, Xihongmen, four village, Minsheng Road, North East six, No. 10 Patentee after: Chen Yutang Address before: 100076, No. six, No. 10, North East Road, Minsheng Road, fourth village, Xihongmen Town, Beijing, Daxing District Patentee before: Beijing Sino US Joint Institute of innovation and international difficult diseases |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 100076, Beijing, Xihongmen Town, fourth village, Minsheng Road, North East six, No. 10, Beijing Sino US joint innovation and Research Institute of international difficult diseases, Daxing District Patentee after: Chen Yutang Address before: 100076, Beijing Town, Daxing District Town, Xihongmen, four village, Minsheng Road, North East six, No. 10 Patentee before: Chen Yutang |
|
ASS | Succession or assignment of patent right |
Owner name: BEIJING SINO-US JOINT INTERNATIONAL DISEASES RESEA Free format text: FORMER OWNER: CHEN YUTANG Effective date: 20120417 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120417 Address after: 100076, Beijing Daxing District Xihongmen town fourth village Minsheng Road North East six 10, Beijing Sino US Joint Innovation Institute of international difficult disease Chen Zhonghua Dean Patentee after: Beijing Sino US Joint Institute of innovation and international difficult diseases Address before: 100076, Beijing, Xihongmen Town, fourth village, Minsheng Road, North East six, No. 10, Beijing Sino US joint innovation and Research Institute of international difficult diseases, Daxing District Patentee before: Chen Yutang |
|
ASS | Succession or assignment of patent right |
Owner name: BEIJING CHINESE AND FOREIGN XINCHUANG INTERNATIONA Free format text: FORMER OWNER: BEIJING SINA-AMERICA INNOVATION UNITED INTERNATIONAL DIFFICULT DISEASE RESEARCH INSTITUTE Effective date: 20121015 Owner name: BEIJING SINA-AMERICA INNOVATION UNITED INTERNATION Effective date: 20121015 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100076 DAXING, BEIJING TO: 100012 CHAOYANG, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121015 Address after: 100012 Beijing city Chaoyang District Shangli Road No. 201 Beijing Chinese New International Medical Research Institute Patentee after: Beijing new China International Pharmaceutical Research Institute Patentee after: Beijing Sino US Joint Institute of innovation and international difficult diseases Address before: 100076, Beijing Daxing District Xihongmen town fourth village Minsheng Road North East six 10, Beijing Sino US Joint Innovation Institute of international difficult disease Chen Zhonghua Dean Patentee before: Beijing Sino US Joint Institute of innovation and international difficult diseases |
|
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: BEIJING SINA-AMERICA INNOVATION UNITED INTERNATIONAL DIFFICULT DISEASE RESEARCH INSTITUTE Effective date: 20121127 Owner name: BEIJING JINKUI CHINESE MEDICAL RESEARCH INSTITUTE Free format text: FORMER OWNER: BEIJING CHINESE AND FOREIGN XINCHUANG INTERNATIONAL MEDICAL RESEARCH INSTITUTE Effective date: 20121127 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Lin Wanshuo Inventor before: Chen Yutang |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: CHEN YUTANG TO: LIN WANSHUO Free format text: CORRECT: ADDRESS; FROM: 100012 CHAOYANG, BEIJING TO: 100010 DONGCHENG, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121127 Address after: 100010, No. 3-1, building 3, Beijing Hutong, Dongcheng District, China Patentee after: Beijing Jingui Chinese Medicine Research Institute Co. Ltd. Address before: 100012 Beijing city Chaoyang District Shangli Road No. 201 Beijing Chinese New International Medical Research Institute Patentee before: Beijing new China International Pharmaceutical Research Institute Patentee before: Beijing Sino US Joint Institute of innovation and international difficult diseases |
|
DD01 | Delivery of document by public notice |
Addressee: Lin Wanshuo Document name: Notice of termination of patent |
|
DD01 | Delivery of document by public notice | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090701 Termination date: 20200320 |
|
CF01 | Termination of patent right due to non-payment of annual fee |